January 19, 2017
Novocure’s Optune® Now Available at 500 Cancer Treatment Centers in the U.S.
Globally, nearly 800 medical institutions can prescribe Optune to glioblastoma patients ST. HELIER, Jersey–(BUSINESS WIRE)– Physicians at 500 cancer treatment centers in the U.S. have been certified to prescribe Novocure’s (NASDAQ:NVCR) Optune® to newly diagnosed and recurrent glioblastoma (GBM) patients. Optune is Novocure’s wearable, portable,… Read More
learn more
January 10, 2017
Novocure to Report Fourth Quarter and Full Year 2016 Financial Results
January 10, 2017 07:00 AM Eastern Standard Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ:NVCR) announced today that it will report financial results for the fourth quarter and full year 2016 on Thursday, Feb. 23, 2017, before the open of U.S.-based financial markets. Novocure management will host a conference call… Read More
learn more
January 10, 2017
Novocure Announces Preliminary Fourth Quarter and Full Year 2016 Operating Statistics
1,091 active patients at Dec. 31, 2016, an increase of 80 percent versus Dec. 31, 2015 January 10, 2017 07:00 AM Eastern Standard Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ:NVCR), a commercial-stage oncology company developing a proprietary therapy for solid tumors, will provide a business update… Read More
learn more
December 19, 2016
Novocure’s Optune® (NovoTTF-100A) Approved in Japan for the Treatment of Newly Diagnosed Glioblastoma
Optune is the first MHLW-approved therapy in more than a decade to demonstrate statistically and clinically significant extension of survival in newly diagnosed GBM patients December 19, 2016 07:27 AM Eastern Standard Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that the Japanese Ministry… Read More
learn more
December 15, 2016
Novocure to Participate in 35th Annual J.P. Morgan Healthcare Conference
December 15, 2016 07:00 AM Eastern Standard Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that it will participate in the 35th Annual J.P. Morgan Healthcare Conference on Jan. 11, 2017, in San Francisco. William Doyle, Novocure’s Executive Chairman, will speak on behalf of the company and… Read More
learn more
December 12, 2016
Novocure Presents Phase 2 Pilot INNOVATE Trial Results Suggesting Tumor Treating Fields Plus Paclitaxel may be Safe as First-Line Treatment and may Improve Survival of Patients with Recurrent Ovarian Cancer
Topline results demonstrate strong efficacy signals and support planning of phase 3 pivotal trial of TTFields in recurrent ovarian cancer December 12, 2016 04:00 PM Eastern Standard Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) presented data on Dec. 12, 2016, from its phase 2 pilot… Read More
learn more
December 12, 2016
Novocure Presents Second Cohort of Phase 2 Pilot PANOVA Trial Results Suggesting Tumor Treating Fields Plus Nab-Paclitaxel and Gemcitabine may be Safe as First-Line Treatment and may Improve One-Year Survival Rate of Patients with Advanced Pancreatic Cancer
Progression free survival and one-year survival rate of patients treated with Tumor Treating Fields plus nab-paclitaxel and gemcitabine were more than double those of nab-paclitaxel and gemcitabine-treated historical controls No serious adverse events related to TTFields were reported December 12, 2016 04:00 PM Eastern… Read More
learn more
December 8, 2016
Novocure Announces Agenda for Research and Development Day on Dec. 12, 2016
Speakers will share new data from Novocure’s phase 2 pilot trials in pancreatic and ovarian cancers December 08, 2016 07:42 AM Eastern Standard Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today the agenda for the company’s research and development day for analysts and investors, which will… Read More
learn more
November 18, 2016
Long-Term Analysis of All 695 Patients Enrolled in Novocure’s Phase 3 Pivotal Trial in Newly Diagnosed Glioblastoma Confirms Successful Interim Analysis Results and Demonstrates Superior Two- and Four-Year Survival Rates
Patients treated with Optune® together with temozolomide demonstrated a significant increase in progression free and overall survival compared to patients treated with temozolomide alone EF-14 patients treated with Optune together with temozolomide experienced a 70 percent improvement in survival rate at four years compared to… Read More
learn more
November 17, 2016
Novocure Presents Interim STELLAR Results at IASLC Suggesting Treatment with Tumor Treating Fields Plus Chemotherapy may Extend Survival of Patients with Mesothelioma
One-year survival rates of patients treated with Tumor Treating Fields combined with pemetrexed and cisplatin or carboplatin were more than 58% greater than historical control data No device-related serious adverse events have been reported to date November 17, 2016 07:30 AM Eastern Standard Time… Read More
learn more
